OKYO OKYO Pharma

OKYO Pharma Limited - Upcoming Presentation

OKYO Pharma Limited - Upcoming Presentation

LONDON, July 31, 2020 (GLOBE NEWSWIRE) -- OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that Kunwar Shailubhai, Ph.D., the Company’s CEO, will share insight into OKYO’s development pipeline and upcoming milestones during an investor webinar, hosted by RedChip Companies, on Sunday, August 2, 2020. A live Q&A session with Dr. Shailubhai will follow the presentation. A link to a recording of the presentation will be provided on Monday morning via RNS Reach.

About OKYO

OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.

Enquiries:

OKYO Pharma LimitedWilly Simon+44 (0)20 7495 2379
Optiva Securities Limited

Robert Emmet+44 (0)20 3981 4173

For further information, please visit the Company's website at

EN
31/07/2020

Underlying

OKYOOKYO Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OKYO Pharma

 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordina...

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the pricing of an underwritten public offering (the “Offering”) of 10,815,000 ordinary shares at an offering price of $1.85 per ordinary share. The Company has granted the underwriter a 30-day option to purchase up to an additional 1,622,250 ord...

February 13, 2026 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Public Offering of Ordinary Shares

OKYO Pharma Announces Public Offering of Ordinary Shares LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it intends to offer to sell its ordinary shares in an underwritten public offering (the “Offering”). All of the ordinary shares are to be sold by the Company. The Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the ...

February 12, 2026 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Transition of At-The-Market Equity Offering Faci...

OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it has transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners LLC, a leading healthcare-focused investment bank as the sales agent, replacing its previous ATM facility with B. Riley Securities Inc. ...

February 11, 2026 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Strengthens World Class Leadership Team with Appointment o...

OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company’s development program in neuropathic corneal pain (NCP), leveraging urcosimod’s FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class opht...

February 10, 2026 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results fo...

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that an abstract on its lead candidate, urcosimod (formerly OK-101), has been accepted for presentation at the prestigious 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. ...

January 30, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch